Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Integrin alpha V beta 8

Integrin alpha V beta 8

Brief Information

Name:integrin alpha V/beta 8
Target Synonym:alphavbeta8 integrin
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

 Integrin alpha V beta 8 ELISA

Immobilized Rat Integrin alpha V beta 8 (ITGAV&ITGB8) Heterodimer, His Tag&Tag Free (Cat. No. IT8-R52E1) at 5 μg/mL (100 μL/well) can bind Biotinylated Human Latent TGF-Beta 1, His,Avitag (Cat. No. TG1-H82Qb) with a linear range of 0.2-13 ng/mL (QC tested).

Integrin alpha V beta 8 MALS images

The purity of Rat Integrin alpha V beta 8 (ITGAV&ITGB8) Heterodimer, His Tag&Tag Free (Cat. No. IT8-R52E1) is more than 90% and the molecular weight of this protein is around 200-230kDa verified by SEC-MALS.

Synonym Name

Integrin alpha V beta 8,ITGAV&ITGB8


Integrin alpha V beta 8 (ITGAV & ITGB8 or ITGAVB8) is expressed in yolk sac, placenta, brain perivascular astrocytes, Schwann cells, renal glomerular mesangial cells and pulmonary epithelial cells. Unlike other alpha V integrins, ITGAVB8 does not appear to assume different activation states, and the cytoplasmic tail does not connect to the cytoskeleton. It binds ligands containing an RGD motif, including vitronectin, fibrin and the latency associated peptide (LAP) of the latent TGF-beta complex. High affinity binding of alpha V beta 8 to LAP allows proteolytic cleavage by MT1-MMP, which releases active TGF-beta. This mechanism differs from that of alpha V beta 6, the other alpha V integrin which can activate TGF-beta from latency through non-proteolytic mechanisms. Downstream effects of TGF-beta activation include control of cell growth and associated vascularization.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Nesvategrast OTT-166(OcuTerra Therapeutics); SF-0166 Phase 2 Clinical Scifluor Life Sciences Inc, OcuTerra Therapeutics Inc Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration Details
CRB-601 CRB-601 Phase 1 Clinical Uc San Francisco, Corbus Pharmaceuticals Holdings Inc Solid tumours Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message